Advertisement
Screener

ACTINIUM PHARMACEUTICALS, INC. (ATNM) Amortization of Debt Issuance Costs

2.8 / 5 stars · 68/120 Roast Me

ACTINIUM PHARMACEUTICALS, INC. Amortization of Debt Issuance Costs

ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Amortization of Debt Issuance Costs of $292.69 thousand for the 166-month period ending 2014-03-31, per its 10-Q filed 2014-05-12.

Discontinued › Expense Statement › Operating Expenses

us-gaap:AmortizationOfFinancingCosts · last filed 2014-05-12

  • ACTINIUM PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2012-12-31 was $32.52K.
  • ACTINIUM PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2012-09-30 was $73.77K.
  • ACTINIUM PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2012-06-30 was $72.98K.
  • ACTINIUM PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2012-03-31 was $72.97K.
  • ACTINIUM PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2012 was $252.25K, a 523.70% increase from fiscal 2011.
  • ACTINIUM PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2011 was $40.44K.
Period endAmortization of Debt Issuance Costs 3 monthAmortization of Debt Issuance Costs 6 monthAmortization of Debt Issuance Costs 9 monthAmortization of Debt Issuance Costs 12 monthAmortization of Debt Issuance Costs 151 monthAmortization of Debt Issuance Costs 154 monthAmortization of Debt Issuance Costs 157 monthAmortization of Debt Issuance Costs 160 monthAmortization of Debt Issuance Costs 163 monthAmortization of Debt Issuance Costs 166 month
2014-03-31$292.69K
10-Q · filed 2014-05-12
2013-12-31$292.69K
10-K · filed 2014-02-28
2013-09-30$292.69K
10-Q · filed 2013-11-14
2013-06-30$292.69K
10-Q · filed 2013-08-13
2013-03-31$292.69K
10-Q · filed 2013-05-15
2012-12-31$32.52K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28
$106.30K
derived: sum of 2 quarters · filed 2014-02-28
$179.28K
derived: sum of 3 quarters · filed 2014-02-28
$252.25K
10-K · filed 2014-02-28
$292.69K
10-K · filed 2013-03-29
2012-09-30$73.77K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14
$146.75K
derived: sum of 2 quarters · filed 2013-11-14
$219.72K
10-Q · filed 2013-11-14
2012-06-30$72.98K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13
$145.95K
10-Q · filed 2013-08-13
2012-03-31$72.97K
10-Q · filed 2013-05-15
2011-12-31$40.44K
10-K · filed 2013-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
PMGC Holdings Inc. (ELAB)United States$0.037B
Celularity Inc (CELU)United States$0.038B-0.34
CervoMed Inc. (CRVO)United States$0.038B-1.39
BriaCell Therapeutics Corp. (BCTX)$0.037B
Edesa Biotech, Inc. (EDSA)Canada$0.039B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
Incannex Healthcare Inc. (IXHL)$0.040B-22.32